We Build
Advanced, Affordable and Accessible Surgical Robotic Solutions

SS Innovations International, Inc.
Company Presentation
October 2026
Nasdaq: SSII

Disclaimers

No Offering of Securities

No offer is made by this Company Presentation (this "**Presentation**") to invest in SS Innovations International, Inc. (the "**Company**") or to purchase any of its securities. Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company.

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the **"Securities Act"**), and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward-looking statements. Examples of forward-looking statements include statements regarding the benefits, uses and safety of our products, projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services. In some cases, you can identify forward-looking statements by the use of terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. Actual events or results may differ materially. We undertake no obligation to update any of the forward-looking statements after the date of this Presentation to conform them to actual results. Please refer to the risk factors described in the "Risk Factors" section and other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC.

Statistical and Other Industry and Market Data

This Presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, and management is responsible for the accuracy of such assumptions and data, no independent source has verified such assumptions.

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Our Vision

To continuously improve and deploy our **technologically-advanced**, **cost-effective** surgical robotic systems, while maintaining **affordability** and **accessibility** for the benefit of a larger segment of patients globally

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Snapshot of SS Innovations

- We develop innovative, **differentiated surgical robotic technologies,** highlighted by our:
  - Proprietary **surgical robotic system,** the **SSi Mantra 3**;
  - **Comprehensive suite of surgical instruments**, which support a variety of surgical procedures, including **robotic cardiac surgery** and **robotic pediatric surgery**;
  - AI- and XR-driven **imaging, training and simulation platform**; and
  - Pioneering **telesurgery** capabilities.
- We are backed by a team of leading **surgical robotics experts** and seasoned medical technology executives.
- We are a rapidly growing American company with Indian roots, **expanding globally** and preparing for a potential strategic entry into **Europe** and the **United States**.
- Including the Company's strong foundational market of India, the SSi Mantra **installed base currently spans 12 countries**.

14,681
Multi-Specialty Surgeries

245
SSi Mantra Systems Installed

9
Surgical Specialities

218
Hospitals

192
Validated Surgical Procedures

195
Telesurgeries

755
Robotic Cardiac Surgeries

2022
Year of Commercialization

0
# of Significant Safety Events Reported



Note: Data as of September 30, 2026

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Snapshot of SS Innovations (Continued)



Headquarters	Gurugram, India
Company Domicile	Florida, USA
Employees (June 30, 2026)	486
Year Merged with Avra Medical	2023
Year Uplisted to Nasdaq	2025
Ticker	SSII
Exchange	Nasdaq-CM
Shares Out (October 1, 2026)	~200 mm
Recent Price (October 1, 2026)	$2.75
Market Cap (October 1, 2026)	~$0.6 bn
Insider Ownership (June 12, 2026)	~72%

Systems Installed
(cumulative data)



Revenue
($ millions)



© 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Data as of September 30, 2026; 272 of these procedures were pediatric surgeries

Investment Highlights

1. Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology
2. Large and Growing Total Addressable Market with Favorable Industry Tailwinds
3. Advanced, Cost-Efficient Surgical Robotics Platform – Clinically and Commercially Differentiated
4. Established Presence in India with Global Expansion Underway
5. Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins
6. Strategy to Deliver Long-Term, Sustainable Growth

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology

Sudhir Srivastava, MD, Founder, Chairman & CEO
- Robotic cardiac surgeon with 40+ years of experience
- Pioneered many of the world's first robotic cardiac procedures
- Performed numerous robotic cardiac surgeries and trained surgical teams worldwide
- University of British Columbia, University of Chicago, Alliance Hospital
- Owns ~108.6 million shares, or ~54% of SSII shares outstanding[1]

Vishwajyoti Srivastava, MD, Chief Executive Officer, APAC & Board Member
- Led the development of the OMNI 3D Medical Visualization system
- Serves as the President of OMNI 3D HD to advance existing technological platform for availability in the global surgical and endoscopic marketplace
- Previously served as the VP of Marketing and Technology at the International Centre for Robotic Surgery in New Delhi
- Columbia University, Saint James School of Medicine

Frederic Moll, MD, Vice-Chairman
- Former Chief Development Officer, J&J Medical Devices
- Founder, Intuitive Surgical, Hansen Medical, Auris Health
- Co-Founder & Partner, Sonder Capital Management
- Board Member, PROCEPT BioRobotics, Neptune Medical, Moon Surgical
- Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT
- Owns ~20.8 million shares, or ~10% of SSII shares outstanding[1]

Barry Cohen, COO – Americas & Board Member
- Co-Founder, CEO and Director, Avra Medical Robotics
- Former Director and President, Synalloy Corp.
- Former Chairman of the Board, Wolverine Technologies

Tim Paul Adams, Board Member
- Regional Operating Officer, Ascension
- Former Regional CEO, Tenet Healthcare
- Chairman, Tennessee Hospital Association

Dr. Mylswamy Annadurai, Board Member
- Former Director, Indian Space Research Organization

Somashekhar SP, MD, Board Member
- Robotic Surgeon
- Global Director, Aster International Institute of Oncology

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. As of 9/28/2026; Dr. Sudhir Srivastava's holdings exclude 4,872,287 shares issuable upon exercise of stock options with an average exercise price of $5.00 per share.

Large and Growing Addressable Market with Favorable Industry Drivers

Accelerated Global Adoption of Robotic Surgery

Global Surgical Robotics Market[1]

(in USD billions)



Benefits of Robotic Surgery

Benefits to Patients

- Smaller incisions, reduced trauma, less blood loss
- Less pain and discomfort, faster recovery time, minimal scarring
- Enhanced outcomes and reduced risk of infection

Benefits to Surgeons

- Greater precision, magnified 3D vision, articulated dexterity
- Reduced fatigue and minimized hand tremors (ergonomic systems)
- Enhanced training pathways

Benefits to Hospitals and Payers

- Greater resource utilization
- Improved economics - increased revenue and reduced costs
- Lower complication rates and shorter stays

Underlying Drivers for Robotic-Assisted Surgery

* Aging global population * Rising chronic diseases * Increasing demand from patients, surgeons and hospitals

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Sourced from December 2025 Markets and Markets Surgical Robots Market Report

Large and Growing Addressable Market with Favorable Industry Drivers

Opportunity to Address Global Access

Global Population[1]
(% of total population)



Surgical Robotic Installed Base[1]
(% of total installations worldwide)



Greater than 90% of installed surgical robotic systems are located in the US, EU and Japan -- implying limited access to the rest of the world (~7.3 billion people).[1]

Traditional hurdle to global access: **high cost of acquisition** and **implementation**.

SS Innovations aims to democratize access to surgical robotics in underserved regions of the world with its **advanced** and **cost-effective** SSi Mantra system.

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Estimates sourced from secondary market research

Large and Growing Addressable Market with Favorable Industry Drivers

Significant Market Opportunity in Our Foundational Market of India

More than **2,000 surgeons in India** have been trained in robotic-assisted surgery, including on the SSi Mantra.

	India		United States
Population[1]	1.4 Billion	>	0.34 Billion
Hospitals[2]	~70,000	>	~6,100
Hospital Beds (per 1,000 people)[3]	~1.3	<	~2.8
Da Vinci Robotic Systems Installed[4]	275	<	6,615
SSi Mantra Systems Installed[5]	225		*

1. India data sourced from World Bank Group; US data sourced from the US Census Bureau.
2. India data sourced from INDHEAL; US data sourced from the American Hospital Association.
3. India data sourced from India Brand Equity Foundation report dated May 2026; US data sourced from OECD (Organization for Economic Cooperation and Development).
4. India data as of September 18, 2026, per Intuitive Surgical press release; US data as of June 30, 2026, per Intuitive Surgical 10-Q filing.
5. India data as of September 30, 2026; the SSi Mantra has not been approved for commercialization in the US market – it is currently under FDA review.

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3



3 Vision Cart

3D 4K resolution monitor, identical to the surgeon's console, for OR staff. Also houses the control system for the articulating endoscope and camera and pre-operative guidance software

2 Patient-Side Robotic Arm Carts

Modular robotic arms mounted on individual carts with the option of using 3, 4 or 5 robotic arm configurations

1 Surgical Command Center

Ergonomic open-faced console comprised of a pair of passive 3D glasses, a 3D 4k resolution monitor and a 2D touch monitor for system controls

4 Instrument and Accessories

Comprehensive suite of stapling, energy and core instrumentation for the surgical system under the brand name SSi Mudra

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3 – Surgical Command Center

- Ergonomic Open-Faced Console
- Large 3D 4K Monitor
- Large 2D Touch Monitor for System Controls and DICOM access
- Lightweight Magnetic Hand Controls Design
- Head Tracking Safety Feature
- Digital Ergonomics Control
- Tele Surgery and Tele Proctoring Enabled

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3 – Patient Side Robotic Arm Carts



- Modular Robotic Carts
- Freedom of Patient Docking
- 3/4/5 Patient Cart Connectivity
- Absolute Stability Parking Locks
- Smaller Individual Cart Footprint
- Advanced Touch Screen Controls

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3 – Vision Cart

- Large 3D 4K Monitor for Operating Room Staff
- Inbuilt Multimedia Recording, Playback and Streaming
- 3D 4k ICG Camera System with 0- and 30-degree Endoscope
- Pre-Operative Guidance Software
- UPS Backup
- E-Stop Safety Features
- Standard 5 Robotic Arms Connectivity Control Box

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mudra – Multi Specialty Robotic Instruments

40+[1]
Types of Instruments

7 Degrees of Freedom Articulating Robotic Instruments

10 Use
Life Cycle per Instrument

20+[1]
Cardiac Specialty Instruments
Only company in the world **actively advocating** for robotic cardiac surgery
Untapped market potential in **automated coronary artery bypass surgery**
400+ complex robotic cardiac surgeries performed with the SSi Mantra

Novel Instrument:
Automated Coronary Anastomotic Connector[1]

Novel Instrument:
Multi-Fire Clip Applier[2]



Advanced Instruments:
Selicut Harmonic



Advanced Instruments:
ExpertSeal Vessel Sealer

Advanced Instruments:
Anastoflex Stapler



Cardiac Stabilizer


Valve Retractor - Short


Black Diamond Forceps

Small Bipolar Forceps


Valve Retractor - Long

Debakey Froceps

Cautery Hook

Cautery Spatula


Micro Scalpel

Fine Tip Scissors

Long Tip Forceps

Round Tip Scissors

Cadiere Forceps


Small Titanium Clip Applier

Resano Forceps

The Company has developed **six new 5-millimeter surgical robotic instruments** for clinical use across multiple specialties, including **pediatric**, **cardiac**, and **head and neck** surgery, among other procedures involving smaller anatomical structures.

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Includes instruments under development.
2. Under development.

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies

SSi Guru

XR Tele Proctoring System

- Mixed Reality Headset
- Portable 3D Surgery Viewer
- Interactive Virtual Screens
- CDSCO Approved
- Virtual Tele Illustration Feature
- Proctored over 1,200 miles under 400 ms latency

AR Smart Glasses[1]

3D Visualization System

- 3D HD 1080p vision
- Variable IPD adjustments
- Direct from endoscope video signal processing
- IMU based head tracking

Cognitive Skill Simulator[1]

A different approach to train surgeons

- Overlaid instruments tracking
- Guided procedure steps
- Trains cognition and muscle memory
- Enhancing motor skills through repetition
- Console and VR based learning system





Mixed reality-powered and AI-enabled technologies for better training, visualization, and simulation for the entire surgical team.

1. In development

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

Supported by the SS International Centre for Robotics Surgery ("SSICRS")

SS International Centre for Robotics Surgery

- A premier educational institute for robotic-assisted surgical training
- Subsidiary of SS Innovations
- Located at the Company's headquarters in Gurugram, India

World Class Training Center

- Modern lecture halls and state-of-the-art labs
- Top-tier faculty, including renowned international surgeons
- Multi-specialty training leverages on-site SSi Mantra systems
- Balance of hands-on learning and classroom theory
- Tele-proctoring and engineering-integrated learning

SSICRS

In July 2026, SSICRS **graduated its first class** in a specialized training course designed to provide surgeons with hands-on learning in **robotic-assisted cardiac surgery**. SSICRS will offer training across multiple procedure types, leveraging the SSi Mantra platform as a training tool.



© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Advanced, Cost-Efficient Surgical Robotics Platform

Pioneering Telesurgery Capabilities and Mobile Robotic Telesurgery Unit

SSI MANTRA

195 telesurgeries have been completed with the SSi Mantra surgical robotic system[2]

Jul 2025
IRCAD HQ Strasbourg, France ⟷ 4,000+ miles ⟷ Sri Aurobindo IMS Indore, India

May 2026
Perth, Australia ⟷ 6,250+ miles[3] ⟷ Sri Aurobindo IMS Indore, India

May 2026
Georgetown, Guyana ⟷ 12,500+ miles[3] ⟷ IRCAD Indore, India

July 2026
Bucaramanga, Colombia ⟷ 13,600+ miles[3] ⟷ Mohak Bariatrics Indore, India

World's Longest-Distance Robotic Telesurgery

First system approved for telesurgery in India.[1] We enhance remote surgical access and empower underserved communities through telesurgery, surgical education, mentoring, and real-time data insights.

March 2026 - SSi Mantra approved for telesurgery in **Indonesia** and the **Philippines**

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. CDSCO approval (India)
2. As of 9/30/26
3. Communication line distance

Advanced, Cost-Efficient Surgical Robotics Platform

The SSi MantrAsana Tele-Surgeon Console Facilitates Telesurgery from “Anywhere”



Enables Portability

Requires Less Space

Facilitates Telesurgery from Physician’s Offices and other Locations with Limited Working Space

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Established Presence in India with Global Expansion Underway

World-Class R&D and Manufacturing Facilities to Support Growth and Cost Efficiency

R&D, Manufacturing, Assembly, and Operations in Gurgaon, Delhi **National Capital Region (India)**

Proximity to **New Delhi International airport** with excellent connectivity with all parts of the world

~91,000 sq ft space spread over three floors as of June 30, 2026

486 employees as of June 30, 2026

20 Systems per month Current Production Capacity

Plan to expand manufacturing to match growth

© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Established Presence in India with Global Expansion Underway

SSi Mantra 3 Is Demonstrating Rapid Adoption Across Various Geographies

Overview of Installed Base



Installed base *Academic center*

Cumulative Installed Base



245
as of 9/30/26

Completed Procedures



14,681
as of 9/30/26

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Established Presence in India with Global Expansion Underway

Global Expansion - Regulatory Approvals

India CDSCO 2023	**Guatemala** 2023	**Indonesia** 2024	**Ecuador** 2024
Philippines 2025	**Ukraine** 2025	**UAE** 2025	**Colombia** 2025
Oman 2025	**Iraq** 2025	**Sri Lanka** 2026	**Kenya** 2026
Nepal 2026	**Guyana** 2026	**US FDA** Anticipated Q1 '27	**EU CE** Anticipated Q4 '26
Australia, Brunei, Laos, Morocco, Thailand, Vietnam Anticipated 2026		**Chile, Nigeria, Mauritius** Approval Not Required	

In 2025, SS Innovations generated approximately **87%** of its revenue from **India**.

We expect the percentage of total revenue coming from the **rest of the world** to significantly expand over time.

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Established Presence in India with Global Expansion Underway

Estimated Regulatory Timelines

US FDA

Current Stage

- FDA Q Sub 2024
- 510(k) Technical Dossier Preparation[1]
- 510(k) Submitted Multi-Specialty Indications Q4 2025
- AINN Received April 8, 2026 180 days to respond
- Clinical for Chole Indication and HF trials Q3 2026
- Response to AINN October 5, 2026
- FDA Review / Market Clearance Q1 2027[2]

EU CE Mark

Current Stage

- Route of Conformity to Notified body
- Certification EN ISO 13485 Completed
- Initial Review - Application and Technical File March 2025
- Stage 1 Audit Desktop Q4 2025
- Stage 2 Audit On Site Q2 2026
- Technical File Review Q3 2026
- CE Marking Q4 2026[2]

Notified body – Szutest, Germany

1. Human factor validation in the US
2. Dependent on the outcome of the review process

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins

Revenue
($ millions)



Revenue Mix
(%)



Gross Margin
(%)



© 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Recurring revenue defined as systems on rental / lease, instruments and consumables sales and maintenance service fees

First Half 2026 – Robust Growth in Revenue and SSi Mantra Installations and Procedures







© 2026 SS INNOVATIONS INTERNATIONAL, INC.

Growth Strategy

Platform **Value**	Focus on Large **Multi-Specialty Hospitals**	Target **Leading Surgeons and Thought Leaders** to Raise Awareness and Encourage Widespread Adoption
• Advanced Technology	• Secure Initial Placements	• Indian Medical Advisory Board
• Lower Cost	• Expand # of Physicians using Mantra 3	• International Advisory Board
• Ease of Training	• Increase System Utilization at Each Hospital	• Medical Conferences
• Improved Patient Outcomes	• Place Additional Systems at Each Hospital (Go Deeper)	• Robotic Surgery Training Programs
• Differentiated Features (e.g., Cardiac)		• Strategic Partners (e.g., Johns Hopkins)

Continuously Improve and **Innovate** our top-tier robotics platform through **New Product Development** and **Enhanced Technology**.

Maintain **Stronghold in India**, grow in **Select Underserved Countries** with low penetration and cost barriers, and pursue **Established Markets**.

In the **United States**, after FDA approval, focus on **ASCs** and **Smaller Hospitals** while leveraging the SSi Mantra's differentiated **Cardiac** surgery capabilities.

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

Appendix

Financial Summary

SS Innovations **Statement of Operations** (in USD)	Twelve Months Ended			Six Months Ended		Three Months Ended	
	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2025	June 30, 2025	June 30, 2026	June 30, 2025	June 30, 2026
Revenue	5,875,314	20,649,528	42,484,747	15,120,915	25,041,075	10,000,305	13,939,709
Gross Profit	725,528	8,452,366	19,544,255	7,002,266	12,428,171	5,915,058	7,100,950
Gross margin	*12.3%*	*40.9%*	*46.0%*	*46.3%*	*49.6%*	*59.1%*	*50.9%*
Operating (loss) income	(20,273,984)	(18,975,962)	(8,194,034)	(5,623,766)	(5,896,932)	97,014	(2,271,354)
Net (loss) income	(20,878,292)	(19,151,197)	(8,160,947)	(5,938,044)	(6,243,921)	(256,691)	(2,661,350)
Diluted EPS	$(0.14)	$(0.11)	$(0.06)	$(0.03)	$(0.03)	$(0.00)	$(0.01)
Diluted shares	152,069,825	181,203,673	198,699,461	195,502,268	207,369,897	202,835,698	209,422,550

Balance Sheet (in USD)	June 30, 2026
Cash[1]	22,295,891
Current assets	71,453,952
Total assets	96,982,013
Current liabilities	31,891,727
Long term debt	-
Total stockholders' equity	53,401,223

SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

1. Includes restricted cash of $8,648,461

Summary of SSi Mantra Installations

Annual Installations

Year	#	Growth
2022	3	-
2023	15	400%
2024	47	213%
2025	103	119%



Cumulative Installations[1]

Year	#	Growth
2022	3	-
2023	18	500%
2024	65	261%
2025	168	158%



Quarterly Installations

Year	#	Growth
Q1'24	9	-
Q2'24	10	-
Q3'24	6	-
Q4'24	22	-
Q1'25	15	67%
Q2'25	23	130%
Q3'25	27	350%
Q4'25	38	73%
Q1'26	26	73%
Q2'26	30	30%



SSii © 2026 SS INNOVATIONS INTERNATIONAL, INC.

[1]At end of period

Note: all growth % figures are year over year comparisons

Investor Contact:

EQUITY GROUP

Kalle Ahl, CFA
(303) 953-9878
kalle.ahl@theequitygroup.com

SSii

www.ssinnovations.com
investors@ssinnovations.org

 © 2026 SS INNOVATIONS INTERNATIONAL, INC.